t
Diaceutics PLC will announce its unaudited results for the half year ended 30 June 2024 on Tuesday, 17 September 2024. On the same date, the company will host a webinar presentation for analysts and investors at 1330 BST and a separate investor presentation via Investor Meet at 1630 BST.
| Date | 9 Sept 2024 |
| Time | 07:00:10 |
| Category | Results |
| ID | 2990D |
Diaceutics - Notice of Results & Presentations
Belfast and London, 9 September 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, will announce its unaudited results for the half year ended 30 June 2024 on Tuesday, 17 September 2024.
Analyst Presentation:
A webinar presentation for analysts and investors will be held at 1330 BST (0830 ET) on Tuesday, 17 September 2024. Those wishing to attend can register using the following link:
Investor Meet Presentation:
A webinar presentation for investors will be held via the Investor Meet platform at 1630 BST (1130 ET) on Tuesday, 17 September 2024. The presentation is open to all existing and potential shareholders and registration can be completed via the following link:
https://www.investormeetcompany.com/diaceutics-plc/register-investor
Questions can be submitted pre-event via your Investor Meet Company dashboard up until 0900 BST the day before the meeting or at any time during the live presentation. Investors who already follow Diaceutics on the Investor Meet Company platform will automatically be invited.
Enquiries:
|
Diaceutics PLC |
|
|
Ryan Keeling, Chief Executive Officer Nick Roberts, Chief Financial Officer |
Tel: +44 (0)28 9040 6500
|
|
|
|
|
Canaccord Genuity Limited (Nomad & Broker) |
Tel: +44 (0)20 7523 8000 |
|
Simon Bridges, Andrew Potts, Harry Rees |
|
|
Alma Strategic Communications |
Tel: +44(0)20 3405 0205 |
|
Caroline Forde, Kinvara Verdon
|
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.